CoChat

A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation

Open access
Camilleri, Michael, Kerstens, René, Rykx, An, Vandeplassche, Lieve · 2008 · New England Journal of Medicine

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation. METHODS: In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once daily, for 12 weeks. The primary efficacy end point was the proportion of patients having three or more spontaneous, complete bowel movements per week, averaged over 12 weeks. Secondary efficacy end points were derived from daily diaries and validated questionnaires completed by patients. Adverse events, clinical laboratory values, and cardiovascular effects were monitored. RESULTS: Efficacy was analyzed in 620 patients. The proportion of patients with three or more spontaneous, complete bowel movements per week was 30.9% of those receiving 2 mg of prucalopride and 28.4% of those receiving 4 mg of prucalopride, as compared with 12.0% in the placebo group (P<0.001 for both comparisons). Over 12 weeks, 47.3% of patients receiving 2 mg of prucalopride and 46.6% of those receiving 4 mg of prucalopride had an increase in the number of spontaneous, complete bowel movements of one or more per week, on average, as compared with 25.8% in the placebo group (P<0.001 for both comparisons). All other secondary efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment. CONCLUSIONS: Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation. Larger and longer trials are required to further assess the risks and benefits of the use of prucalopride for chronic constipation. (ClinicalTrials.gov number, NCT00483886 [ClinicalTrials.gov].).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa0800670

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Research works printed but not linked: 3

  1. 10.1111/j.1572-0241.1999.01642.x · doi:10.1111/j.1572-0241.1999.01642.x · Paper page
  2. 10.1111/j.1572-0241.2002.05843.x · doi:10.1111/j.1572-0241.2002.05843.x · Paper page
  3. Schiller LR, 2004, Rev Gastroenterol Disord, 4, S43

Cited by

See all 581

Metadata

Authors
Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L.
Affiliations
Mayo Clinic (US)
Venue
New England Journal of Medicine
Published
2008-05-29
Volume
358
Issue
22
Pages
2344-2354
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2068454300
Cited by
576
References
36
Citations by year
2026: 13 · 2025: 16 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 28 · 2020: 28 · 2019: 19 · 2018: 29 · 2017: 33 · 2016: 38 · 2015: 33 · 2014: 46 · 2013: 50 · 2012: 49
FWCI
45.65
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
  • Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
Keywords
prucalopride, serotonin receptor agonists, 5-HT4 receptor agonist, stool frequency, treatment-related adverse events, cardiovascular safety
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Benzofurans, Chronic Disease, Constipation, Defecation, Double-Blind Method, Electrocardiography, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Serotonin Receptor Agonists, Laxatives, Serotonin 5-HT4 Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.